Hyaluronic acid-conjugated liposomes loaded with dexamethasone: A promising approach for the treatment of inflammatory diseases

Nanomedicines for targeted pulmonary delivery: receptor-mediated strategy and alternatives

“…Japiassu et al designed an HA-decorated liposome for the delivery of dexamethasone to AMs, which is a classical anti-inflammatory drug. 53 The in vitro results showed that the TNF-α level secreted by M1-type AMs was reduced by about 57% with the treatment of dexamethasone-loaded HAliposomes, which was significantly higher than the dexamethasone-loaded blank liposome group (about 30%). The in vivo LPS-induced lung inflammation model also showed a similar outcome, confirming the targeting capacity of the HA-decorated liposomes for AMs.…”

Revolutionizing Therapy: Nanomaterials in Liposomes Redefine the Future of Medicinal Drugs

“…In this perspective, Ref. [63] investigated the potential use of dexamethasone (Dex), a corticosteroid with anti-inflammatory and immunosuppressive properties, in treating inflammatory lung diseases such as asthma, acute lung injury, and COVID-19. Despite its therapeutic benefits, prolonged systemic administration of Dex can result in adverse side effects.…”

CD44 in Bladder Cancer

“…HA-based therapeutics have been developed for clinical applications. HA-dexamethasone nanoparticles have been shown to strengthen the delivery of the anti-inflammatory dexamethasone to site-specific locations in patients suffering from a variety of conditions, including hearing loss [ 91 , 92 ], osteoarthritis of the knee [ 93 ], lung inflammation, and other disorders [ 94 ]. For bladder cancer, HA-based clinical applications include conjugating chemotherapeutic agents to HA, thereby allowing cells with high levels of HA receptors, such as CD44, to uptake the agents.…”